ChartMill · Sep 7, 2026
Arcutis Biotherapeutics (NASDAQ:ARQT) Delivers High Growth with Improving Fundamentals
Arcutis (ARQT) passes Navellier's 8 growth rules: EPS, revenue, and cash flow surging. A top pick for growth investors.
AR
NASDAQ · ARQT
Arcutis Biotherapeutics, Inc.
Healthcare · Biotechnology
$23.38
Down-$0.46 (-1.93%)
Updated Sep 11, 2026, 9:19 AM
SID Score
4.2/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 3.3B
- P/E ratio
- -214.29
- Dividend yield
- 0.00%
- 52-week range
- $19.30 – $29.84
- Volume
- 1.79M
- Avg. volume
- 1.63M
Price performance
ARQT price history
1M range · 20 trading sessions · Daily adjusted prices
ARQT closed at $23.38 after 20 trading sessions, down 9.49% for the selected period.
- Last close
- $23.38
- Period change
- -9.49%
- Period low
- $23.38
- Period high
- $26.54
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 10, 2026 | $23.70 | $23.84 | $23.25 | $23.38 | 1.79M |
| Sep 9, 2026 | $24.05 | $24.46 | $23.74 | $23.84 | 2.31M |
| Sep 8, 2026 | $24.84 | $25.13 | $24.09 | $24.39 | 4.56M |
| Sep 4, 2026 | $23.27 | $24.02 | $23.27 | $23.90 | 1.63M |
| Sep 3, 2026 | $24.13 | $24.13 | $23.47 | $23.66 | 1.12M |
| Sep 2, 2026 | $23.95 | $24.45 | $23.40 | $23.85 | 1.95M |
| Sep 1, 2026 | $23.79 | $24.11 | $23.54 | $23.75 | 1.1M |
| Aug 31, 2026 | $23.75 | $24.07 | $23.21 | $23.97 | 1.52M |
| Aug 28, 2026 | $24.60 | $24.88 | $23.74 | $23.78 | 1.54M |
| Aug 27, 2026 | $24.95 | $25.15 | $24.60 | $24.87 | 2.2M |
| Aug 26, 2026 | $24.85 | $25.495 | $24.45 | $25.14 | 1.91M |
| Aug 25, 2026 | $25.01 | $25.34 | $24.745 | $24.86 | 1.19M |
| Aug 24, 2026 | $24.80 | $25.21 | $24.49 | $24.78 | 1.13M |
| Aug 21, 2026 | $25.49 | $25.67 | $24.7332 | $25.08 | 2.16M |
| Aug 20, 2026 | $26.50 | $26.56 | $24.53 | $25.35 | 3.29M |
| Aug 19, 2026 | $27.00 | $27.19 | $26.37 | $26.46 | 1.03M |
| Aug 18, 2026 | $25.51 | $26.71 | $25.49 | $26.54 | 1.97M |
| Aug 17, 2026 | $26.20 | $26.341 | $25.51 | $25.61 | 1.71M |
| Aug 14, 2026 | $25.39 | $26.235 | $25.28 | $26.19 | 1.11M |
| Aug 13, 2026 | $26.57 | $26.65 | $25.765 | $25.83 | 1.59M |
Latest ARQT news
The latest Smart Investors Daily articles mentioning ARQT.
Stock researchCompany · Overview
ARQT research
Overview
Company profile and research snapshot.
Company profile
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $32.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 6, 2026 | Morgan Stanley | Overweight | — |
| Aug 6, 2026 | Guggenheim | Buy | — |
| Aug 6, 2026 | Needham | Buy | — |
| May 7, 2026 | Needham | Buy | — |
| Mar 2, 2026 | Mizuho | Outperform | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 4, 2026
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WESTLAKE VILLAGE, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the grant of an aggregate of 57,000 restricted stock units (RSUs) of Arcutis common stock to 11 newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022
Yahoo · Sep 2, 2026
Arcutis Management to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
WESTLAKE VILLAGE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will present at the Morgan Stanley 24th Annual Global Healthcare Conference, taking place September 14-16, 2026, in New York. Details for the Company’s participation are as follows: Fireside Chat: Wednesday, September 16, 2026, at 1:50 p.m.
Yahoo · Aug 28, 2026
Arcutis Biotherapeutics (ARQT) Faces A Valuation Test, Is It Still A Bargain?
Arcutis Biotherapeutics Stock Performance Snapshot Arcutis Biotherapeutics (ARQT) has drawn investor attention after recent share price moves, with the stock down about 12% over the past month but up roughly 16% over the past 3 months. The company, which focuses on dermatological treatments such as its lead product ZORYVE, now carries a market value of about US$3.16b and recently closed at US$24.87 as of 25 August 2026. Looking at the bigger picture, Arcutis Biotherapeutics has seen mixed...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
